Lucent 1 & Lucent 2 Studies

Lucent 1 & Lucent 2 Studies

Information About This Study:

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizmab in Conventional-Failed and Biologic-Failed Patents with Moderately to Severely Active Ulcerative Colitis.

Study Number:



Ulcerative Colitis

Open to Volunteers

Please call Allegiance Research Specialists to see if you qualify: 414-727-8131